Tricyclic Peptides for the Development of Therapeu.. (CyPepUTICS)
Tricyclic Peptides for the Development of Therapeutics
Date du début: 1 juin 2014,
Date de fin: 31 mai 2016
Peptide macrocycles can bind with high affinity and selectivity to protein targets and are an attractive class of molecules for the development of therapeutics. Recently, a phage display-based strategy was developed that allowed to generate potent bicyclic peptide antagonists (Heinis, C., et al., Nat. Chem. Biol., 2009). While bicyclic peptides with nanomolar affinities to a range of protein targets could be generated, it was more difficult to obtain high-affinity binders to some proteins, particularly to those having flat surfaces and no clefts or cavities. Herein, I propose to develop rigid, tricyclic peptides that should, due to a more defined three-dimensional structure, bind to flat surfaces similar as antibodies. Two formats are envisioned for the synthesis of tricyclic peptides: in the first one, a linear peptide is anchored via four cysteine residues to a small molecule while in the second format, bicyclic peptides will be generated and their two peptide rings are connected via Huisgen cycloaddition reaction to impose an additional conformational constraint. Phage-encoded combinatorial libraries of these peptide folds will be generated and subjected to affinity selections. Tricyclic peptide binding to a variety of biological targets including (a) the well-characterized cancer-associated targets EGFR and HER2, and (b) the more challenging target of the antibiotic vancomycin, the short peptide D-Ala-D-Ala, will be developed.
Bonjour, vous êtes sur la plateforme Région Sud Provence-Alpes-Côte d’Azur dédiée aux programmes thématiques et de coopération territoriale. Une équipe d’experts vous accompagne dans vos recherches de financements.
Contactez la Région Sud Provence-Alpes-Côte d'Azur
Vous pouvez nous écrire en Anglais, Français et Italien